Please ensure Javascript is enabled for purposes of website accessibility

Inovio Pharmaceuticals Stock Soars on Encouraging HIV Vaccine Readout

By George Budwell – Updated May 24, 2017 at 1:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Inovio Pharmaceuticals' experimental HIV vaccine is off to a promising start.

What happened

Shares of the clinical-stage biotech Inovio Pharmaceuticals (INO 4.54%) gained as much as 38% today due to a positive early-stage readout for its experimental HIV vaccine called Pennvax-GP.

Digging into the details, the company reported that 71 out of 76 (93%) evaluable participants exhibited either a CD4+ or CD8+ cellular immune response to at least one of the vaccine's four antigens. The long and short of it is that this experimental HIV vaccine just produced some of the strongest immune responses ever observed in a human clinical trial, according to Inovio.  

Hand holding bottle that says HIV vaccine, with a syringe and a stethoscope next to it.

Image Source: Getty Images.

So what

An effective and safe HIV vaccine that can prevent and/or cure patients would easily generate billions in sales in short order. As proof, Gilead Sciences (GILD 2.08%), the market share leader in terms of HIV drug sales, rakes in around $13 billion annually for its HIV product line. If Inovio can capture even a sliver of this multi-billion-dollar market, it would be a ginormous win for shareholders, especially in light of the company's present market cap of only $657 million. 

Now what

Before investors get too excited, though, it's important to remember that this HIV vaccine is years away from even a possible regulatory filing. Moreover, Inovio also has a disappointing track record when it comes to developing clinical candidates in a timely fashion. The $25 million National Institute of Allergy and Infectious Diseases contract that originally provided funding for this vaccine, for instance, was signed roughly eight years ago, back in 2009. That's not exactly an encouraging timeline from a value-creation standpoint.

Having said that, I think that these promising preliminary results might be enough to warrant a deeper dive from leaders in the space, like Gilead. After all, Gilead arguably has the most to lose if a competitor introduces a disruptive HIV vaccine into the market, and it has tons of cash to sign licensing deals. In other words, Inovio may be able to monetize this promising clinical asset sooner, rather than later. Stay tuned.

George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short June 2017 $70 calls on Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.84 (4.54%) $0.08
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$63.93 (2.08%) $1.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.